@article{948863cb58be4184b2888e2505c8e0db,
title = "Closing the information gap between clinical and postmarketing trials: the case of dabigatran",
keywords = "dabigatran, randomized controlled trial, subgroup analysis, health technology assessment, vitamin K antagonists, postmarketing trials, clinical trials, ethics, medical ethics, effect uncertainty, health care expenses, medicine, cardiovascular disease, randomized controlled trials as topic",
author = "Rolden, \{Herbert J A\} and Grutters, \{Janneke P C\} and \{van der Wilt\}, \{Gert Jan\} and Maas, \{Angela H E M\}",
year = "2015",
month = apr,
day = "17",
doi = "10.1093/ehjcvp/pvv020",
language = "English",
volume = "1",
pages = "153--156",
journal = "European Heart Journal - Cardiovascular Pharmacotherapy",
issn = "2055-6845",
publisher = "Oxford University Press",
number = "3",
}